Cost-Effectiveness of Lenalidomide-Plus-Dexamethasone in Multiple Myeloma Patients Who Have Received at Least One Prior Therapy: A South Korean Perspective.

treatments with respect to PFS were estimated through a survival analysis of patient-level data (Celgene data on file). Due to the potential of crossover/subsequent treatment options induced bias, OS was estimated using a quantitative relationship between PFS and OS from a censored normal weighted Tobit regression model, based on 153 MM studies containing 230 treatment arms7. In this study, Félix et all (2013) estimated that a 2.5 month (95% confidence interval, 1.7–3.2) increment in median OS is expected for each additional month in median PFS (Table 1). COST-EFFECTIVENESS OF LENALIDOMIDE-PLUSDEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY: A SOUTH KOREAN PERSPECTIVE Vandewalle B1, Félix J1, Almeida JM1, Valeska A1 , Yeo R2